Ocugen Inc
NASDAQ:OCGN

Watchlist Manager
Ocugen Inc Logo
Ocugen Inc
NASDAQ:OCGN
Watchlist
Price: 0.72 USD Market Closed
Market Cap: 209.8m USD

Ocugen Inc
Investor Relations

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 56 full-time employees. The company went IPO on 2014-12-03. The firm's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine candidate is focused on developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The company is developing OCU200, a biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.

Show more
Loading

Earnings Calls

2024 Q3
Nov 8, 2024
Show Transcript
Previous
Next
Ocugen Achieves Significant Milestones in Gene Therapy Development
2024 Q3
Nov 8, 2024

In the third quarter of 2024, Ocugen made notable strides, securing Health Canada's approval for its Phase III OCU400 trial and FDA's expanded access program for retinitis pigmentosa, enhancing treatment access. Their lead candidate, OCU400, aims to treat multiple gene mutations, targeting a substantial market with approximately 300,000 affected patients. A $30 million debt financing extends their operational runway into early 2026. The company anticipates completing OCU400's Phase III enrollment by mid-2025, seeking regulatory submissions by mid-2026 and potential commercialization in 2027. Additionally, clinical trials for OCU410 and OCU410ST are advancing well, addressing unmet needs for geographic atrophy and Stargardt disease.

Show Full Analysis

Management

Dr. Shankar Musunuri M.B.A., Ph.D.
Co-Founder, CEO & Chairman
No Bio Available
Dr. Uday B. Kompella Ph.D.
Co-founder & Independent Director
No Bio Available
Dr. Arun Upadhyay Ph.D.
Chief Scientific Officer and Head of Research & Development
No Bio Available
Mr. Ramesh Ramachandran C.M.A., CPA, M.B.A.
Principal Financial Officer & Principal Accounting Officer
No Bio Available
John Kouch J.D.
General Counsel
No Bio Available
Ms. Tiffany J. Hamilton M.B.A.
AVP & Head of Corporate Communications
No Bio Available
Ms. Kristen Craft
Head of People & Culture
No Bio Available
Mr. Michael Shine M.B.A.
Senior Vice President of Commercial
No Bio Available
Ms. Jyothy Pillai M.S.
VP & Head of Regulatory & Quality
No Bio Available
Dr. Huma Qamar CMI, M.D., M.P.H.
Chief Medical Officer
No Bio Available

Contacts

Address
PENNSYLVANIA
Malvern
263 Great Valley Parkway
Contacts
+14843284701.0
ocugen.com